


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.



BIOSYSEN LIMITED

生物系統工程有限公司

*(formerly known as “Legend Strategy International Holdings Group Company Limited
枋濬國際集團控股有限公司”)*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1355)

RESULTS OF VALID ACCEPTANCES OF THE RIGHTS SHARES AND NUMBER OF UNSUBSCRIBED RIGHTS SHARES SUBJECT TO THE COMPENSATORY ARRANGEMENTS UNDER THE RIGHTS ISSUE

Reference is made to the prospectus of Biosysen Limited (the “**Company**”) dated 4 August 2026 (the “**Prospectus**”) in relation to the Rights Issue of the Company on the basis of one (1) Rights Share for every two (2) existing Shares held on the Record Date at the Subscription Price of HK\$0.068 per Rights Share. Unless the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Prospectus.

RESULTS OF THE VALID ACCEPTANCES OF THE RIGHTS SHARES

As at the Record Date, (i) there were 596,532,580 Rights Shares offered under the Rights Issue (“**Offered Shares**”); and (ii) there were no Non-Qualifying Shareholders and the number of the NQS Unsold Rights Shares was nil. The Board announces that as at 4:00 p.m. on Tuesday, 18 August 2026, being the Latest Time for Acceptance, a total of 15 valid acceptances for a total of 340,531,862 Rights Shares had been received, representing approximately 57.09% of the total number of Offered Shares. Accordingly, the Rights Issue was undersubscribed by 256,000,718 Rights Shares, representing approximately 42.91% of the total number of the Offered Shares, which will be subject to the Compensatory Arrangements.

THE COMPENSATORY ARRANGEMENTS

The Company will make arrangements described in Rule 7.21(1)(b) of the Listing Rules to dispose of 256,000,718 Unsubscribed Rights Shares by offering such Unsubscribed Rights Shares to independent placees for the benefit of Shareholders to whom they were offered by way of the Rights Issue. On 24 June 2026 (after trading hours), the Company entered into the Placing Agreement with the Placing Agent in relation to the Placing of the Unsubscribed Rights Shares to independent placees on a best effort basis.

Pursuant to the Placing Agreement, the Company has appointed the Placing Agent to place the Unsubscribed Rights Shares during the Placing Period to independent placees on a best effort basis, and any premium over the aggregate amount of (i) the Subscription Price for those Rights Shares; and (ii) the expenses of the Placing Agent (including any other related costs and expenses), that is realised from the Placing (the “**Net Gain**”) will be paid to the relevant No Action Shareholders. The Placing Agent will, on a best effort basis, procure, by not later than 4:00 p.m. on Wednesday, 2 September 2026, acquirers for all (or as many as possible) of those Unsubscribed Rights Shares at a price not less than the Subscription Price. Any Unsubscribed Rights Shares and the NQS Unsold Rights Shares which are not placed under the Compensatory Arrangements will not be issued by the Company and the size of the Rights Issue will be reduced accordingly.

Net Gain (if any) will be paid (without interest) to the No Action Shareholders as set out below on pro rata basis (but rounded down to the nearest cent):

- A. the relevant Qualifying Shareholders (or such persons who hold any nil-paid rights at the time such nil-paid rights are lapsed) whose nil-paid rights are not validly applied for in full, by reference to the extent that Shares in his/her/its nil-paid rights are not validly applied for; and
- B. the relevant Non-Qualifying Shareholders with reference to their shareholdings in the Company on the Record Date.

If and to the extent in respect of any Net Gain, any No Action Shareholders become entitled on the basis described above to an amount of HK\$100 or more, such amount will be paid to the relevant No Action Shareholder(s) in Hong Kong Dollars only and the Company will retain individual amounts of less than HK\$100 for its own benefit.

An announcement of the results of the Right Issue (including the results of the Placing and the Net Gain) is expected to be published on the websites of the Stock Exchange and the Company on Monday, 7 September 2026.

WARNING OF THE RISKS OF DEALINGS IN THE SHARES

Shareholders and potential investors of the Company should note that each of the Rights Issue and the Placing is subject to the fulfilment of certain conditions. If any of the conditions of the Rights Issue and/or the Placing are not fulfilled, the Rights Issue and/or the Placing will not proceed.

Subject to the fulfilment of the conditions of the Rights Issue, the Rights Issue will proceed on a non-underwritten basis irrespective of the acceptance of the provisionally allotted Rights Shares. Any Unsubscribed Rights Shares together with the NQS Unsold Rights Shares will be placed to independent places on a best effort basis through the Placing. Accordingly, if the Rights Issue is undersubscribed, the size of the Rights Issue will be reduced. Qualifying Shareholders who do not take up their assured entitlements in full and Non-Qualifying Shareholders, if any, should note that their shareholdings in the Company may be diluted, the extent of which will depend in part on the size of the Rights Issue.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares. Any person who is in any doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional advisor(s).

By order of the Board
Biosysen Limited
Lee Tsz Yan
Executive Director

Hong Kong, 25 August 2026

As at the date of this announcement, the Board comprises Ms. Lee Tsz Yan as executive Director; Mr. Cheung Ching Mo and Mr. Hu Xinglong as non-executive Directors; and Mr. Wu Jilin, Mr. Lam Cheung Shing Richard and Mr. So Yin Wai as independent non-executive Directors.